Lyell Immunopharma Inc. (LYEL), a late-stage clinical company, released on Wednesday results from the first quarter, and provided updates on the developing pipeline of drug candidates.
The company specializes in next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of various cancer indications.
Q1 2026:
The company reported a net loss of $24.15 million in Q1 2026, while in the same period of 2025, the net loss was $52.19 million.
Revenue was reported at $2000, down from a revenue of $7000 in the first quarter of 2025. Revenue is generated from research and collaboration agreements.
Research and development expenses (R&D) were $36.60 million, compared to $43.44 million in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $260.97 million.
In March 2026, the company closed the second $50 million tranche of its July 2025 equity private placement at $25.61 per share, following the achievement of a clinical milestone in the PiNACLE trial.
Pipeline Highlights:
Ronde-cel is a dual-targeting CD19/CD20 CAR-T antibody developed to treat large B-cell lymphoma (LBCL). The therapy received a regenerative medicine advanced therapy (RMAT) designation from the FDA for treating adults with relapsed/refractory LBCL (R/R LBCL).
The 3L+ cohort was expanded from the single-arm, pivotal Phase 1/2 PiNACLE trial, with primary endpoints set at overall response rates (ORR) and duration of response. Additional data is expected by the second half of 2026, and pivotal data by mid-2027, when the company plans to file a biologics license application (BLA) with the FDA.
The PiNACLE-H2H Phase 3 randomized control trial is evaluating ronde-cel against standard-of-care therapies like axicabtagene ciloleucel or lisocabtagene maraleucel in treating R/R LBCL.
LYL273 is a next-generation guanylyl cyclase C (GCC) CAR-T cell therapy targeting metastatic colorectal cancer (mCRC) and other GCC-expressing cancers. Lyell acquired global rights to the drug in November 2025. LYL273 was granted a fast-track designation from the FDA for the treatment of mCRC and is currently enrolling participants in the Phase 1 trial.
Data is expected in the second half of this year and will establish the dosage values in the upcoming Phase 2 trial.
LYEL closed Wednesday at $20.85, up 1.12%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.